Drug intelligence / Profile preview

nicotine C-11

Development stage
Phase 4
Lead developer
Wake Forest University Health Sciences
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
Administration
Intravenous, Inhalation
01

Overview

Nicotine C-11 (also known as [11C]nicotine) is a radiopharmaceutical research compound used as a positron emission tomography (PET) imaging tracer. It consists of the alkaloid nicotine labeled with the radioactive isotope carbon-11, typically synthesized by the methylation of nornicotine using [11C]methyl iodide. Primarily utilized in clinical research, it allows for the visualization and quantification of nicotine kinetics and biodistribution in the human brain and body, particularly following smoking or intravenous administration. Studies have demonstrated that when inhaled via cigarette smoke, the tracer reaches significant brain levels within seconds. While it effectively tracks the rapid uptake and distribution of nicotine, it is generally considered unsuitable for mapping specific nicotinic cholinergic receptor (nAChR) binding sites in the human brain due to high non-specific binding and rapid kinetics that do not meet the stringent criteria for receptor-specific tracers.

Other names
C-11 labeled nicotineC11 labeled nicotineC 11 labeled nicotine[11C]nicotine11C-nicotinecarbon C-11 nicotinenicotine C-11
02

Targets

α4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)CHRNA7 (α7 nicotinic receptor)

Beyond the preview

Go deeper on nicotine C-11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on nicotine C-11.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call